Presentation is loading. Please wait.

Presentation is loading. Please wait.

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy  Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Published bySusanne Kristin Dieter Modified over 6 years ago

Similar presentations

Presentation on theme: "Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy  Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy."— Presentation transcript:

1 Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy  Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy Franke-Beckmann, MD, Jürgen Funck, MD, Martin Kimmig, MD, Ludger Klimek, MD, Roland Knecht, MD, Volker Stephan, MD, Bente Tholstrup, MSc, Christian Weißhaar, MD, Friedrich Kaiser, MD  Journal of Allergy and Clinical Immunology  Volume 123, Issue 1, Pages e7 (January 2009) DOI: /j.jaci Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Trial flow diagram. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Rhinoconjunctivitis medication use, entire grass pollen season. Left, Percentage of subjects with medication use. Right, Total percentage of diary records (days) with medication use. ∗Statistically significant difference between treatment groups (Fisher exact test). #Statistically significant difference between treatment groups in the prevalence of days with use of the concerned relief medication (generalized linear mixed model). Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Immunology results reported as change from baseline for each of the 2 treatment groups at different time points, with 95% CIs. A, Mean levels of P pratense–specific IgE antibodies. B, Mean levels of P pratense–specific IgG4 antibodies. C, IgE-blocking factor, P pratense (mean values). Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Distribution of subjects in each treatment group with regard to length of treatment evaluated by number of days from the day of first tablet intake to the day of last tablet intake. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy  Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy."

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,
Does BCG vaccination protect against childhood asthma

Does BCG vaccination protect against childhood asthma
Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial  Peter Bager, PhD, John Arnved, MD, Steen.

Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial  Peter Bager, PhD, John Arnved, MD, Steen.
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.
Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Similar presentations

Ads by Google